Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, HER2/EGFR in Cancer Research, and CAR-T cell therapy research.
A single-nucleus and spatial transcriptomic atlas of the COVID-19 liver reveals topological, functional, and regenerative organ disruption in patients
Scalable prediction of symmetric protein complex structures
Building smart CAR T cell therapies: The path to overcome current challenges
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
System-wide transcriptome damage and tissue identity loss in COVID-19 patients
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
The spatial landscape of lung pathology during COVID-19 progression
Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
<i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts